Latest News on DCGO

Financial News Based On Company


Advertisement
Advertisement

DocGo Announces CEO Transition and Separation Agreement

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8841025/docgo-announces-ceo-transition-and-separation-agreement/
DocGo Inc. has announced a Transition Services and Separation Agreement with CEO Lee Bienstock as the company seeks a successor before his employment agreement expires on December 31, 2026. Bienstock will continue as CEO until March 31, 2027, with provisions for a monthly salary, equity awards, benefits, and a 2026 performance bonus, plus a $785,000 severance. Analysts currently rate DCGO stock as a Buy with a $1.00 price target, while TipRanks' AI Analyst, Spark, assigns a Neutral score due to weak financial performance despite some improving operating metrics.

DocGo announces CEO transition agreement with Lee Bienstock

https://www.investing.com/news/sec-filings/docgo-announces-ceo-transition-agreement-with-lee-bienstock-93CH-5026664
DocGo Inc. announced a Transition Services and Separation Agreement with CEO Lee Bienstock, who will remain in his role until December 31, 2026, and then assist with leadership transition through March 31, 2027. Bienstock will receive a monthly salary of $90,000 during this period, along with accelerated vesting of equity awards and a severance package of $785,000. This transition comes as the company continues its search for a new CEO and follows a recent report of wider-than-expected Q3 2026 losses and a reduced price target from Needham.

Form 8K DocGo Inc For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-docgo-inc-for-13-november-93CH-4957942
This article announces that DocGo Inc. filed a Form 8K on November 13, 2026. The filing is noted by Investing.com and includes the stock symbol DCGO, which was down 7.73% at the time of publication. The content of the 8K filing itself is not detailed in this short announcement.

DCGO: DocGo Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

https://quantisnow.com/insight/docgo-inc-filed-sec-form-8-k-leadership-update-financial-statements-6791325
DocGo Inc. has filed an SEC Form 8-K indicating a leadership transition for CEO Lee Bienstock. Mr. Bienstock will remain in his role through March 31, 2027, receiving a monthly salary of $90,000 during this period, while the company searches for a successor. He is also set to receive a $785,000 severance payment, contingent on certain conditions, upon the expiration of his employment agreement on December 31, 2026.

DocGo announces CEO transition agreement with Lee Bienstock By Investing.com

https://uk.investing.com/news/stock-market-news/docgo-announces-ceo-transition-agreement-with-lee-bienstock-93CH-4982055
DocGo Inc. has announced a transition agreement with CEO Lee Bienstock, who will remain in his role until a successor is found, and then serve as a senior advisor through March 31, 2027. Bienstock will receive a monthly salary, vest in outstanding equity awards, and be eligible for a 2026 annual bonus. Upon transition, he will receive a severance payment and COBRA reimbursement, subject to specific conditions.
Advertisement

DCGO: DocGo Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

https://www.quantisnow.com/insight/docgo-inc-filed-sec-form-8-k-leadership-update-financial-statements-6791325
DocGo Inc. has filed an SEC Form 8-K detailing a leadership transition for its CEO, Lee Bienstock. Mr. Bienstock will remain in his role through a transition period until March 31, 2027, receiving a monthly salary of $90,000 and continued equity vesting, while the company searches for a successor. He is also slated to receive a $785,000 severance payment, subject to certain conditions.

DocGo Inc. (NASDAQ:DCGO) Analysts Are Cutting Their Estimates: Here's What You Need To Know

https://simplywall.st/stocks/us/healthcare/nasdaq-dcgo/docgo/news/docgo-inc-nasdaqdcgo-analysts-are-cutting-their-estimates-he
DocGo Inc. (NASDAQ:DCGO) recently missed its quarterly earnings, with revenues of US$73m falling short of analyst predictions and a larger-than-forecast statutory loss of US$0.17 per share. Following these results, analysts have revised their 2027 forecasts, trimming revenue estimates to US$309.1m and increasing per-share loss expectations to US$0.28. Despite these downgrades, the consensus price target remains steady at US$1.88, although the company's projected revenue growth is expected to be slower than the broader industry.

DocGo Inc. (DCGO) stock price, news, quote and history

https://au.finance.yahoo.com/quote/DCGO/
This article provides a comprehensive overview of DocGo Inc. (DCGO) stock, including its current price, historical performance, and key financial metrics. It details the company's operations in mobile healthcare services, financial highlights, and analyst recommendations. The stock has experienced significant declines year-to-date and over multiple years, but analysts maintain a "Buy" rating with a target price of $1.38.

Needham cuts DocGo stock price target on revenue guidance cut By Investing.com

https://ca.investing.com/news/stock-market-news/needham-cuts-docgo-stock-price-target-on-revenue-guidance-cut-93CH-4946332
Needham has lowered its price target for DocGo shares from $3.00 to $1.00, while maintaining a Buy rating, following the company's mixed third-quarter results and a cut in fiscal 2026 revenue guidance. DocGo is planning to exit or restructure unprofitable revenue streams, aiming for profitability by fiscal 2026 and positive adjusted EBITDA in fiscal 2027, despite challenges like leadership turnover and ongoing cash burn. The stock is currently trading significantly lower over the past year, though InvestingPro analysis suggests it remains undervalued.

DocGo FY26 guidance cut to $300m, misses $306.5m estimate

https://scanx.trade/stock-market-news/companies/docgo-fy26-guidance-cut-300m-misses-306-5m-estimate/55806459
DocGo Inc. has reduced its fiscal year 2026 sales guidance to $300 million, falling below the previous outlook of $305.0 million to $310.0 million and missing the analyst consensus estimate of $306.5 million. This adjustment signals a more conservative revenue trajectory and a material reset in expectations for the upcoming fiscal year. The new single-point guidance is $6.5 million below analyst estimates and $5.0 million lower than the bottom end of the prior range.
Advertisement

DocGo 3Q 2026: Revenue $73.43M, EPS ($0.17) — 10-Q Summary

https://www.tradingview.com/news/tradingview:8bc6632b8e59c:0-docgo-3q-2026-revenue-73-43m-eps-0-17-10-q-summary/
DocGo (DCGO) reported a third-quarter revenue of $73.43 million, a 3.7% increase year-over-year, driven by higher Transportation Services activity. The company's net loss narrowed by 40.2% to ($16.6M), resulting in a diluted EPS of ($0.17), an improvement of 39.3% compared to the prior year, primarily due to lower operating expenses and the absence of impairment charges. Mobile Health Services revenue declined as migrant-related services decreased, though partly offset by virtual care revenue.

Quarterly losses narrowed at DocGo (DCGO), but nine-month operating cash flow turned negative.

https://www.stocktitan.net/sec-filings/DCGO/10-q-doc-go-inc-quarterly-earnings-report-b98ccee3ab84.html
DocGo Inc. (DCGO) reported a narrower net loss of $16.6 million in Q3 2026 compared to $27.8 million a year prior, with revenues increasing to $73.4 million. Despite this, the company's operating cash flow for the first nine months turned negative, using $17.5 million compared to providing $44.9 million in 2025. DocGo maintains $19.1 million in unrestricted cash and plans cost and cash-use reductions to address concerns about its continued operations, including a merger with Hicuity Health.

DocGo Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:734674:0-docgo-q3-2026-earnings-call-is-live/
DocGo's quarterly earnings call for Q3 2026 has commenced, where executives will discuss the latest financial results and answer questions from analysts. This call offers insights into the company's performance and potential future developments beyond the initial earnings release numbers. Management commentary during these calls can significantly influence market perception, especially concerning future demand, margins, and capital expenditures.

DocGo to Announce Third Quarter 2026 Results on Monday, November 9, 2026

https://www.01net.it/docgo-to-announce-third-quarter-2026-results-on-monday-november-9-2026/
DocGo Inc. (Nasdaq: DCGO) announced it will release its financial results for the third quarter ended September 30, 2026, after market close on Monday, November 9, 2026. The company will also host a conference call and webcast at 5:00 p.m. ET on the same day to discuss these results. DocGo provides technology-enabled mobile health and medical transportation services.

DocGo Inc Q3FY26 Results: Announcement set for Nov 9

https://scanx.trade/stock-market-news/companies/docgo-inc-q3fy26-results-announcement-set-nov-9/55262108
DocGo Inc. is scheduled to release its financial results for the third quarter ended September 30, 2026, after the market close on Monday, November 9, 2026. Management will host a conference call and webcast at 5:00 pm ET on the same day to discuss these results. The article also provides details for investors and analysts to access the conference call via telephone or webcast.
Advertisement

DocGo Inc. (DCGO) Seasonal returns chart

https://uk.finance.yahoo.com/quote/DCGO/seasonality/
This article presents a seasonal returns chart for DocGo Inc. (DCGO), displaying the average monthly price return for the period between 2020 and 2026. The stock is currently showing a significant gain of 15.92% as of the market open.

DocGo Inc. Estimates – NASDAQ:DCGO

https://www.tradingview.com/symbols/NASDAQ-DCGO/financials-estimates/
This article provides an overview of DocGo Inc. (NASDAQ: DCGO) financial estimates on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows for comparison of actual results with average, high, and low estimates, and visualization of trends over time.

New loan financing brings a warrant for up to 4M DocGo (DCGO) shares.

https://www.stocktitan.net/sec-filings/DCGO/8-k-doc-go-inc-reports-material-event-721b79ac3d58.html
DocGo (DCGO) has amended and restated its credit agreement, securing an additional $12.5 million funded loan (Term Loan B) and another $12.5 million (Term Loan C) tied to a merger. As part of this financing, DocGo issued the administrative agent a fully vested warrant to purchase up to 4 million shares of common stock at an exercise price of $0.5039 per share. This warrant, exercisable through October 1, 2036, could lead to dilution for existing shareholders if exercised.

BTIG Maintains DocGo(DCGO.US) With Hold Rating

https://www.moomoo.com/news/post/1000457845/btig-maintains-docgo-dcgous-with-hold-rating
BTIG has reiterated its Hold rating for DocGo (DCGO.US). This indicates that the analyst firm is not recommending buying or selling the stock at this time, suggesting they view its current valuation as fair or believe there are no significant catalysts for a strong price movement in the near term.

Promising Penny Stocks To Consider In October 2026

https://simplywall.st/stocks/us/media/nasdaq-msgm/motorsport-games/news/promising-penny-stocks-to-consider-in-october-2026
This article highlights three promising penny stocks for October 2026: DocGo (DCGO), Motorsport Games (MSGM), and Blue Ridge Bankshares (BRBS). Each company is analyzed for its financial health, recent performance, and future outlook, with considerations for growth opportunities despite potential risks associated with penny stocks. The market has seen an 11% rise in the past year, with earnings expected to grow by 18% annually.
Advertisement

DocGo Price Target Maintained With a $3.00/Share by Needham

https://www.moomoo.com/news/post/1000452090/docgo-price-target-maintained-with-a-3-00-share-by
Needham has reiterated its Buy rating for DocGo (NASDAQ:DCGO) and maintained a price target of $3.00 per share. This suggests that Needham continues to see significant upside potential for the company's stock.

Needham reiterates Buy rating on DocGo, $3 price target

https://www.tradingview.com/news/tradingview:5401915517454:0-needham-reiterates-buy-rating-on-docgo-3-price-target/
Needham has reiterated its Buy rating on DocGo (DCGO) with a $3.00 price target, suggesting a significant upside of 715.2% from its previous closing price. The positive outlook is attributed to DocGo's strategic acquisition of Hicuity Health's virtual care platform, which is expected to boost revenue and operational synergies. Additionally, the analyst notes strong financial management and a proactive debt repayment strategy, enhancing investor confidence.

DocGo (DCGO) Stock Analysis Report | Ratings, Financials & Performance

https://es.benzinga.com/quote/DCGO/report
This report provides a comprehensive analysis of DocGo (DCGO) stock, covering its general information, financial health, and past performance. DocGo is a mobile health services provider with two segments: Mobile Health Services and Transportation Services. The analysis includes key financial indicators like operating margin, quick ratio, and debt-to-equity, along with a review of its 5-year Sharpe ratio.

DocGo Inc.(NasdaqCM: DCGO) dropped from S&P Global BMI Index

https://www.marketscreener.com/news/docgo-inc-nasdaqcm-dcgo-dropped-from-s-p-global-bmi-index-ce785adbd98bf725
DocGo Inc. (NasdaqCM: DCGO) has been removed from the S&P Global BMI Index. This announcement follows several recent company activities, including presenting at a global healthcare conference, reporting Q2 2026 earnings where net loss widened and revenue fell, and acquiring Hicuity Health, Inc. The company also updated its earnings guidance and extended its equity buyback plan.

DocGo at Morgan Stanley healthcare conference: margin push takes center stage

https://ng.investing.com/news/stock-market-news/docgo-at-morgan-stanley-healthcare-conference-margin-push-takes-center-stage-93CH-2698670
DocGo presented its strategy at the Morgan Stanley 24th Annual Global Healthcare Conference, aiming for adjusted EBITDA profitability by year-end through revenue optimization, margin improvement, and cost cuts. The company detailed plans to exit underperforming markets, automate back-office functions, and leverage its Hicuity Health acquisition to bridge hospital and home-based care. Despite recent stock performance challenges, DocGo emphasized its technology-enabled mobile health platform and commitment to improving outcomes to drive future growth and profitability.
Advertisement

DCGO | DocGo Inc. Common Stock Financials - Revenue Breakdown

https://www.quiverquant.com/stock/DCGO/financials/revenue_breakdown/
This page provides a detailed financial overview of DocGo Inc. (DCGO), focusing on its revenue breakdown, though specific segment and geographic revenue data are noted as unavailable. It also includes sections on insider trading, institutional holdings, analyst ratings, and a company profile. The platform aims to offer comprehensive financial insights for investors.

Norton Rose Fulbright advises DocGo on acquisition of Hicuity Health

https://www.nortonrosefulbright.com/en/news/c2b301ce/norton-rose-fulbright-advises-docgo-on-acquisition-of-hicuity-health
Norton Rose Fulbright advised DocGo Inc. on its acquisition of Hicuity Health, a virtual care provider, and related debt financing with Perceptive Advisors. The acquisition, valued at approximately US$52 million in assumed debt, is set to expand DocGo's virtual and in-home healthcare platform. Perceptive Advisors also committed an additional US$50 million in debt financing to support DocGo's growth.

DocGo Raises SteadyMD Earnout Liability To $5 Million From $2.3 Million As Telehealth Revenue Outlook Improves

https://pulse2.com/docgo-raises-steadymd-earnout-liability-to-5-million-from-2-3-million-as-telehealth-revenue-outlook-improves/
DocGo has increased its estimated contingent consideration liability for the SteadyMD acquisition from $2.3 million to $5 million, reflecting a more optimistic revenue outlook for the telehealth business. This adjustment resulted in a $2.7 million fair-value loss in the first half but indicates an expected improvement in SteadyMD's performance. The stronger outlook for SteadyMD is crucial for DocGo as it faces declining revenues from migrant-related government programs, making growth from new businesses vital for future financial health and liquidity.

Top Penny Stocks To Watch In August 2026

https://simplywall.st/stocks/us/materials/otc-lqmt/liquidmetal-technologies/news/top-penny-stocks-to-watch-in-august-2026
This article identifies three penny stocks—DocGo (DCGO), NET Power (NPWR), and Liquidmetal Technologies (LQMT)—for investors to watch in August 2026. Despite facing challenges typical of smaller companies like unprofitability and high volatility, these companies exhibit strong financial health indicators such as low debt and sufficient cash runways. The article advises investors to look for robust financials and clear growth trajectories in this segment.

Canaccord Genuity Group Reaffirms "Hold" Rating for DocGo (NASDAQ:DCGO)

https://www.marketbeat.com/instant-alerts/canaccord-genuity-group-reaffirms-hold-rating-for-docgo-nasdaqdcgo-2026-08-18/
Canaccord Genuity Group has reiterated its "Hold" rating for DocGo (NASDAQ:DCGO), maintaining a $1.00 price target, which implies an 85.9% upside from its current share price of $0.54. Analyst sentiment for DocGo is mixed, with a consensus "Hold" rating and an average target price of $2.38 among six analysts. DocGo's shares recently dropped 24.2% to $0.54, while institutional investors hold 56.44% of the company's stock.
Advertisement

DocGo stock price target maintained at $2.50 by Stifel

https://m.investing.com/news/analyst-ratings/docgo-stock-price-target-maintained-at-250-by-stifel-93CH-4865267?ampMode=1
Stifel maintained a Buy rating and $2.50 price target for DocGo (NASDAQ:DCGO) despite the company reporting Q2 revenue and EBITDA below consensus. DocGo is acquiring Hicuity Health, a virtual care provider, which Stifel believes could be synergistic and accelerate growth. The firm views 2026 as a transition year as DocGo aims for breakeven EBITDA by the end of 2026 and trades at 0.1 times revenue, reflecting current risk and reward.

Press Release: DocGo Announces Second Quarter 2026 Results

https://www.moomoo.com/hans/news/post/74815633/press-release-docgo-announces-second-quarter-2026-results?futusource=news_newspage_recommend
This press release from DocGo announces the company's financial results for the second quarter of 2026. Further details about these results would be contained within the full document of the press release.

DocGo (NASDAQ:DCGO) Receives Buy Rating from Needham & Company LLC

https://www.marketbeat.com/instant-alerts/docgo-nasdaqdcgo-receives-buy-rating-from-needham-company-llc-2026-08-18/
Needham & Company LLC has reaffirmed its "buy" rating for DocGo (NASDAQ:DCGO) and set a price target of $3.00, suggesting a potential upside of 322.48% from its current price. Despite this, the stock has an overall "Hold" rating from analysts with an average price target of $2.38. DocGo is an integrated healthcare company providing on-demand and mobile healthcare services through customized medical clinics and a digital care platform.

DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast

https://finance.yahoo.com/healthcare/articles/docgo-shares-tumble-earnings-miss-102612459.html
DocGo (NASDAQ:DCGO) shares dropped significantly after the company reported weaker-than-expected second-quarter 2026 results and substantially increased its projected full-year adjusted EBITDA loss. The mobile healthcare provider's revenue was impacted by the wind-down of migrant-related contracts, and its profitability outlook worsened, leading to investor concern. The acquisition of Hicuity Health also adds integration risk while the company faces a negative market backdrop and Nasdaq listing compliance issues.

DocGo Releases Q2 2026 Financial Results

https://news.alphastreet.com/docgo-releases-q2-2026-financial-results/
DocGo Inc. reported a wider-than-expected diluted loss of $0.16 per share for Q2 2026 and revenue of $73.4 million, falling short of analyst expectations. The company attributes the miss to its restructuring efforts away from migrant services, though core operations excluding migrant programs showed a 19% revenue climb. DocGo provided full-year revenue guidance between $305.0 million and $310.0 million, and analyst consensus remains cautiously balanced with 4 buys and 4 holds.
Advertisement

DocGo posts Q2 miss, cuts adjusted EBITDA outlook

https://m.investing.com/news/earnings/docgo-posts-q2-miss-cuts-adjusted-ebitda-outlook-93CH-4863953?ampMode=1
DocGo (NASDAQ:DCGO) reported a Q2 earnings and revenue miss, delivering a loss of -$0.16 per share against an estimated -$0.10, and revenue of $73.4 million versus a $75.4 million consensus. The company also significantly lowered its full-year adjusted EBITDA outlook to -$17 million to -$22 million. Despite the financial miss and outlook cut, DocGo's shares were up 1% in after-hours trading, possibly due to the announcement of its definitive agreement to acquire virtual care provider Hicuity Health.

DocGo (NASDAQ: DCGO) warns on liquidity as losses widen

https://www.stocktitan.net/sec-filings/DCGO/10-q-doc-go-inc-quarterly-earnings-report-e74f1ce0f82c.html
DocGo (NASDAQ: DCGO) reported a net loss of $34.69 million on revenues of $148.98 million for the first six months of 2026, widening from a $24.37 million net loss on $176.45 million in revenue during the same period in 2025. The company also indicated a going-concern risk due to ongoing operating losses and non-compliance with a minimum liquidity covenant under its credit agreement. DocGo is actively negotiating with its lender and exploring cost-reduction and cash-preservation strategies, including a potential replacement term loan and shifting compensation to stock, to address its liquidity issues.

DocGo to acquire virtual care company Hicuity Health

https://www.mobihealthnews.com/news/docgo-acquire-virtual-care-company-hicuity-health
DocGo has announced its agreement to acquire Hicuity Health, a virtual care company, by assuming its $52 million existing debt. This deal will make Hicuity a wholly-owned subsidiary of DocGo's Ambulnz Holdings. The Series F preferred shareholder of Hicuity will receive DocGo shares, with potential for more if DocGo's market capitalization reaches $250 million within three years.

Earnings call transcript: DocGo misses Q2 2026 estimates as stock falls after hours

https://www.investing.com/news/transcripts/earnings-call-transcript-docgo-misses-q2-2026-estimates-as-stock-falls-after-hours-93CH-4864072
DocGo reported Q2 2026 results that missed Wall Street expectations, with an adjusted loss per share of $0.16 and revenue of $73.4 million. The company's stock fell 11.28% after hours despite a regular-session gain, due to the earnings miss, a wider full-year loss outlook, and plans for a Hicuity Health acquisition. DocGo aims for positive adjusted EBITDA run rate by the end of 2026, driven by revenue growth, margin recovery, and cost efficiencies.

DocGo Inc. (DCGO) Surpasses Q2 Earnings Estimates

https://finance.yahoo.com/markets/stocks/articles/docgo-inc-dcgo-surpasses-q2-213502305.html
DocGo Inc. (DCGO) reported Q2 earnings of $0.16 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.04 per share. Despite this earnings beat, the company's revenues of $73.43 million missed the consensus estimate and were lower than the previous year. The stock has underperformed the S&P 500 year-to-date, and its future performance will likely depend on management's commentary and evolving earnings expectations.
Advertisement

DocGo (NASDAQ:DCGO) Posts Earnings Results, Misses Estimates By $0.06 EPS

https://www.marketbeat.com/instant-alerts/docgo-nasdaqdcgo-posts-earnings-results-misses-estimates-by-006-eps-2026-08-17/
DocGo (NASDAQ:DCGO) announced its quarterly earnings, reporting a loss of $0.16 per share, missing analyst expectations by $0.06, and revenue of $73.42 million, below the $75.35 million consensus. Despite the earnings miss, the stock rose 6.4% to $0.71, with trading volume exceeding its daily average. Analysts hold a "Hold" rating on DocGo with an average target price of $2.38, and institutional investors own 56.44% of the company's shares.

DocGo Inc. 2026: Revenue $73.42M, EPS ($0.16) — 10-Q Summary

https://www.tradingview.com/news/tradingview:2b9cf63ff3fa7:0-docgo-inc-2026-revenue-73-42m-eps-0-16-10-q-summary/
DocGo Inc. reported a Q2 2026 revenue of $73.42M and a diluted loss per share of ($0.16), showing a decline compared to the prior year. This decrease was primarily due to the wind-down of migrant-related Mobile Health contracts, though Transportation Services saw modest growth and the company implemented measures like headcount reduction and AI investment to manage costs and pursue new opportunities.

DocGo (NASDAQ: DCGO) to buy Hicuity virtual care business and tap $50M in loans

https://www.stocktitan.net/sec-filings/DCGO/8-k-doc-go-inc-reports-material-event-18fa5786c1bc.html
DocGo (NASDAQ: DCGO) announced an agreement to acquire virtual care provider Hicuity Health through a stock-for-equity transaction and the assumption of Hicuity's debt, which is estimated to be approximately $52 million. Perceptive Advisors has committed up to an additional $50 million in new senior secured term loans for DocGo. This acquisition is expected to add approximately $65 million in trailing-12-month revenue and $4.5 million in adjusted EBITDA for Hicuity Health, expanding DocGo's offerings into high-acuity virtual clinical care.

DocGo Announces Second Quarter 2026 Results

https://finance.yahoo.com/healthcare/articles/docgo-announces-second-quarter-2026-202000361.html
DocGo (Nasdaq: DCGO) announced its second-quarter 2026 financial results, revealing total revenue of $73.4 million, a decline from $80.4 million in Q2 2025 primarily due to the wind-down of migrant-related programs. Excluding these programs, revenue increased 19% year-over-year. The company also announced a definitive agreement to acquire virtual care provider Hicuity Health and new term loan funding from Perceptive Advisors, while narrowing its full-year 2026 revenue guidance to $305-$310 million and updating adjusted EBITDA expectations to ($17-$22) million.

DocGo agrees to acquire virtual care provider Hicuity Health, assumes $52M debt

https://www.fiercehealthcare.com/finance/docgo-enters-definitive-agreement-acquire-virtual-care-provider-hicuity-health-assumes-52m
DocGo announced its acquisition of virtual care provider Hicuity Health, including the assumption of approximately $52 million in Hicuity's debt. This move aims to expand DocGo's virtual care offerings, building on its previous acquisition of SteadyMD. The announcement coincided with DocGo's Q2 2026 earnings report, which showed a revenue decline due to the wind-down of migrant-related programs but strong growth in core business lines and record volumes.
Advertisement

Earnings To Watch: DocGo Inc (DCGO) Q2 2026 -- GF Value Sees 151% Upside

https://finance.yahoo.com/markets/stocks/articles/earnings-watch-docgo-inc-dcgo-131714721.html
DocGo Inc (DCGO) is scheduled to release its Q2 2026 earnings on August 17, 2026, with revenue estimated at $75.4 million and an expected loss of $0.06 per share. Analysts have an average target price of $1.88, suggesting a 187.05% upside from the current price of $0.65, while GuruFocus estimates a 151.07% upside based on its GF Value. The company has an "Outperform" brokerage recommendation, despite past earnings missing expectations.

Press Release: DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026

https://www.moomoo.com/news/post/74424971/press-release-docgo-to-announce-second-quarter-2026-results-on
DocGo is scheduled to announce its second quarter 2026 financial results on Monday, August 17, 2026. The company will also host a conference call and webcast to discuss these results. Interested parties can access the webcast or dial in to participate.

DocGo to announce Q2 2026 results on Aug 17

https://scanx.trade/stock-market-news/companies/docgo-to-announce-q2-2026-results-on-aug-17/47911402
DocGo Inc (NASDAQ: DCGO) is scheduled to release its second-quarter 2026 financial results after market close on Monday, August 17, 2026. The company will also host a conference call and webcast at 5:00 p.m. ET on the same day to discuss its quarterly performance. Investors can access the webcast and dial-in details through DocGo's investor relations website.

DocGo to Announce Second Quarter 2026 Results on Monday, August 17, 2026

https://finance.yahoo.com/healthcare/articles/docgo-announce-second-quarter-2026-121600982.html
DocGo Inc. (Nasdaq: DCGO) announced that it will release its financial results for the second quarter ended June 30, 2026, after the markets close on Monday, August 17, 2026. Management will host a conference call and webcast on the same day at 5:00 p.m. ET to discuss these results. The company, a provider of technology-enabled mobile health and medical transportation services, has provided details for accessing the call and webcast.

DocGo (DCGO) seeks 5-day SEC extension for delayed Q2 2026 10-Q filing

https://www.stocktitan.net/sec-filings/DCGO/nt-10-q-doc-go-inc-sec-filing-4486ec861915.html
DocGo Inc. has filed an NT 10-Q notification with the SEC, indicating that its Quarterly Report on Form 10-Q for the period ended June 30, 2026, will be filed late. The company stated that additional time is needed to complete and review financial statements and disclosures, and anticipates filing the report within the five-day extension period allowed under Rule 12b-25. DocGo also confirmed that all other required periodic reports over the past 12 months have been filed and does not foresee any significant change in its results of operations compared to the prior fiscal year.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement